Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer

被引：3
|
作者：
Faltas, Bishoy M. [1 ]
Tagawa, Scott T. [1 ]
机构：
[1] Weill Cornell Med, Meyer Canc Ctr, Div Hematol & Med Oncol, New York, NY 10065 USA
来源：
LANCET | 2017年 / 389卷 / 10064期
关键词：
MULTICENTER;
D O I：
10.1016/S0140-6736(16)32516-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / +
页数：2
相关论文
共 50 条
  • [1] New option for cisplatin-ineligible urothelial cancer
    Dreicer, Robert
    [J]. LANCET ONCOLOGY, 2017, 18 (11): : 1428 - 1430
  • [2] Enfortumab vedotin for cisplatin-ineligible urothelial cancer Comment
    Pignot, Geraldine
    [J]. LANCET ONCOLOGY, 2021, 22 (06): : 748 - 749
  • [3] Immune-checkpoint blockade — durable cancer control
    Elizabeth I. Buchbinder
    F. Stephen Hodi
    [J]. Nature Reviews Clinical Oncology, 2016, 13 : 77 - 78
  • [4] Immune-checkpoint blockade - durable cancer control
    Buchbinder, Elizabeth I.
    Hodi, F. Stephen
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (02) : 77 - 78
  • [5] Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder
    Yuxuan Song
    Tao Xu
    [J]. World Journal of Urology, 2023, 41 : 1697 - 1698
  • [6] Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
    Szabados, Bernadett
    Kockx, Mark
    Assaf, Zoe June
    van Dam, Pieter-Jan
    Rodriguez-Vida, Alejo
    Duran, Ignacio
    Crabb, Simon J.
    Van Der Heijden, Michiel S.
    Pous, Albert Font
    Gravis, Gwenaelle
    Herranz, Urbano Anido
    Protheroe, Andrew
    Ravaud, Alain
    Maillet, Denis
    Mendez, Maria Jose
    Suarez, Cristina
    Linch, Mark
    Prendergast, Aaron
    Tyson, Charlotte
    Stanoeva, Diana
    Daelemans, Sofie
    Rombouts, Miche
    Mariathasan, Sanjeev
    Tea, Joy S.
    Mousa, Kelly
    Sharma, Shruti
    Aleshin, Alexey
    Banchereau, Romain
    Castellano, Daniel
    Powles, Thomas
    [J]. EUROPEAN UROLOGY, 2022, 82 (02) : 212 - 222
  • [7] Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder
    Song, Yuxuan
    Xu, Tao
    [J]. WORLD JOURNAL OF UROLOGY, 2023, 41 (06) : 1697 - 1698
  • [8] Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
    David J. Einstein
    Guru Sonpavde
    [J]. Current Treatment Options in Oncology, 2019, 20
  • [9] Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
    Einstein, David J.
    Sonpavde, Guru
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (02)
  • [10] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
    O'Donnell, Peter H.
    Milowsky, Matthew I.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Mar, Nataliya
    Moon, Helen H.
    Friedlander, Terence W.
    McKay, Rana R.
    Bilen, Mehmet A.
    Srinivas, Sandy
    Burgess, Earle F.
    Ramamurthy, Chethan
    George, Saby
    Geynisman, Daniel M.
    Bracarda, Sergio
    Borchiellini, Delphine
    Geoffrois, Lionnel
    Rey, Jose Pablo Maroto
    Ferrario, Christiano
    Carret, Anne-Sophie
    Yu, Yao
    Guseva, Maria
    Moreno, Blanca Homet
    Rosenberg, Jonathan E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +
12345